FDA Receives $102 million increase in FY 22 Omnibus. Alliance campaign encourages Members of Congress to request increased FDA funding.
Top-Line:
Analysis and Commentary provides detail on the FDA’s FY 22 funding and implications for the FY 23 cycle.
House and Senate pass FY 22 Omnibus Appropriations bill.
FDA Receives $102 million increase in FY 22 Omnibus.
FY 23 Appropriations: Ready, Set, Go.
Alliance campaign encourages Members of Congress to request increased FDA funding.
Don’t miss out on the Alliance’s budget priorities webinar series with FDA leaders.
Patrizia Cavazzoni, MD | CDER | April 4, 1 p.m. | Register
Judith McMeekin | ORA | April 6, 2 p.m. | Register
Susan Mayne, PhD | CFSAN | April 12, 11 a.m. | Register
Steven Solomon, DVM | CVM | April 22, 3 p.m. | Register
Jeff Shuren, MD | CDRH | April 29, 11 a.m. | Register
Peter Marks, MD | CBER | May 10, 1 p.m. | Register
This week’s Analysis and Commentary provides detail on the FDA’s FY 22 funding and implications for the FY 23 cycle
House and Senate Pass FY 22 Omnibus Appropriations bill. The House and Senate agreed on a text and report language for an FY 22 omnibus appropriations bill. The House passed the legislation on November 9 and the Senate completed action last night. Passage avoided the need for another Continuing Resolution, and the bill goes to the White House today for the President’s signature.
House passage was difficult. The COVID-19 supplemental had to be stripped from the bill. Further, Democratic leadership divided the bill into two questions, with both portions having to be adopted for the bill to pass. The Senate considered three amendments, all of which were defeated, before final passage.
FDA Receives $102 Million Increase in FY 22 Omnibus. The increase of $102.4 million dollars would be split $29 million to medical product safety, $29.5 million for food safety, $41.3 million for cross-cutting initiatives. The projects that would be funded are described in this week’s Analysis and Commentary (below). The text and explanatory statement are linked here.
In a release to the media (full text here), the Alliance said: "The Alliance for a Stronger FDA thanks Congressional appropriators for their continued support of the FDA, as reflected in the just-released conference agreement on FY 22 appropriations funding. The $102 million increase (3.2%) is much-needed and will strengthen programs throughout the agency.”
“We are certainly aware that both the House and Senate acknowledged greater FDA needs, by proposing larger increases in their separate bills from last summer. However, the FDA increase is in line with the amount of funds available to the Agriculture/FDA subcommittees and reflects continued Congressional support for a strong, well-funded FDA. Once the President’s FY 23 request is submitted to Congress, the Alliance will be hard at work to see the additional needs for this year and new needs in FY 23 are met through increased appropriations.”
FY 23 Appropriations: Ready, Set, Go. The President delivered his State of the Union address on March 1, an event that traditionally kicks off the coming appropriations cycle. We expect the President’s Budget Request next, but the timing is uncertain. We have heard the week of March 21is the Administration’s target, but we have no confirmation and it seems as likely it would be the following week or slip into April.
Beyond that, Member requests are due soon (see next story) and we expect subcommittee hearings in April. The Alliance will submit testimony to both the House and Senate Agriculture/FDA Subcommittees and encourages our members to do the same.
Alliance Campaign Encourages Members of Congress to Request Increased FDA Funding. During March and April of each year, Members of Congress ask their constituents and interested parties to recommend program funding for the coming fiscal year. In turn, Members formulate a list of their priorities, which they share with subcommittee leadership. Requests can be highly localized (monies to rebuild a bridge) or broadly programmatic(increases for NIH).
Every year, the Alliance reaches out to Members of Congress to encourage them to tell appropriators “Increased FDA funding is one of my priorities.” We would like to broaden our efforts so Congressional offices receive 2 or 3 requests on behalf of FDA, rather than just ours.
Here is a link to an earlier Analysis and Commentary that contains more details. If you are interested in participating, please contact Roger Szemraj of the Alliance staff.
Don’t Miss Out on the Alliance’s Budget Priorities Webinar Series with FDA Leaders. Starting April 4, the Alliance will be holding an FY 23 Budget Priorities Webinar Series, with presentations from the five Center Directors and the Associate Commissioner for Regulatory Affairs.
Patrizia Cavazzoni, MD | CDER | April 4, 1 p.m. | Register
Judith McMeekin | ORA | April 6, 2 p.m. | Register
Susan Mayne, PhD | CFSAN | April 12, 11 a.m. | Register
Steven Solomon, DVM | CVM | April 22, 3 p.m. | Register
Jeff Shuren, MD | CDRH | April 29, 11 a.m. | Register
Peter Marks, MD | CBER | May 10, 1 p.m. | Register
These online events are for Alliance members and media, although we welcome guests. If you are not an Alliance member and would like to participate, please contact Alliance Executive Director, Steven Grossman.